Cardiovascular Inflammation

Cardiovascular inflammation is an underlying component in the evolution and exacerbation of other cardiovascular diseases (CVD) like atherosclerosis, myocarditis, heart failure, and post ischemic injury. Protheragen specializes in MyD88 pathways that seek to develop new therapies that moderate cardiovascular inflammation and tissue damage.

Introduction to Cardiovascular Inflammation

Cardiovascular inflammation is a key driver and not simply a passive element of many CVD. It is caused by multiple reasons which includes dyslipidemia, hypertension, diabetes, infection and tissue trauma. This provokes resident cardiovascular cell activation as well as immune cell recruitment into the myocardium and vascular walls. Recognition of pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) by PRRs like TLRs and IL-1 receptors play crucial roles in starting this inflammatory cascade.

Pathogenesis of Cardiovascular Inflammation

Signaling through MyD88-mediated pathways involving TLRs and IL-1 Receptors in vascular and cardiac myocytes activates NF-κB/AP-1 and pro-inflammatory cytokines' (TNF-Α, IL-1β) and chemokine secretion. This monocyte and neutrophil immune cell recruitment escalates inflammation, endothelial cell dysfunction, inflammatory plaque erosion, and tissue scarring fibrosis. Continuous MyD88 signal leads to chronic structural and functional alterations and glances maladaptive remodeling which suggest a linkage of atherosclerosis and heart failure, and also mark the role of innate immunity.

Fig.1 MyD88 Signaling Leads to Cell Specific Functions in Cardiovascular Disease. (Bayer and Alcaide, 2021)

MyD88-Targeted Therapeutic Development for Cardiovascular Inflammation

Disclaimer: Protheragen focuses on providing preclinical research services. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.

Our Services

Protheragen offers specialized services for MyD88-targeted therapeutic discovery and advanced disease models for cardiovascular inflammation. Our integrated platform leverages specific in vitro and in vivo cardiovascular models to enable the screening and evaluation of MyD88 signaling modulators.

Therapeutic Discovery Platform for Cardiovascular Inflammation

Protheragen's MyD88 discovery platform for Cardiovascular Inflammation focuses on the intricate interplay of innate immunity within the cardiac and vascular tissues. The platform is designed to accelerate the preclinical validation of therapies aimed at disrupting MyD88-dependent pro-inflammatory cytokine networks.

Disease Models Development for Cardiovascular Inflammation

Protheragen provides comprehensive preclinical modeling services for cardiovascular inflammation, including cell-based models, organoid models, and animal models that recapitulate the multifactorial inflammatory processes occurring in the heart and blood vessels.

Cell-based & Organoid models

• Primary Human Endothelial Cell Cultures
• Vascular Smooth Muscle Cell Assays
• Primary Cardiomyocyte Cultures
• Vascular/Cardiac Organoid Models

Animal Models Development

• Atherosclerosis Model
• Myocardial Infarction (MI) Models
• Experimental Myocarditis Models
• Hypertension-Induced Vascular Inflammation Models

Protheragen aggressively pursues therapeutic targets in MyD88-related cardiovascular pathologies through a robust treatment options framework. We build comprehensive proposal tools ranging from disease model development, pharmacokinetics and drug safety evaluation to investigator-initiated trials.

If you are interested in our services, please don't hesitate to contact us.

References

• Bayer, A. L., and P. Alcaide. "Myd88: At the Heart of Inflammatory Signaling and Cardiovascular Disease." J Mol Cell Cardiol 161 (2021): 75-85.
• Olson, M. A., et al. "Discovery of Small Molecule Inhibitors of Myd88-Dependent Signaling Pathways Using a Computational Screen." Sci Rep 5 (2015): 14246.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.